Essential Thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms. It is a condition in which the bone marrow produces too many platelets. Patients with ET have increased numbers of platelets. Red blood cell numbers are generally normal in ET, while white blood cell numbers are normal or slightly elevated in ET.
ET often has an indolent course. Age older than 60 years, previous thrombotic events, driver mutations, and very high platelet counts indicate an increased risk for complications.
Get FREE sample copy at:
https://www.delveinsight.com/report-store/essential-thrombocythemia-ET-market-insights
The Essential Thrombocythemia market report also covers emerging drugs, current treatment practices, Essential Thrombocythemia market share of the individual therapies, current and forecasted Essential Thrombocythemia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Essential Thrombocythemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Essential Thrombocythemia Market Key Facts
As per DelveInsight analysts, total prevalent population of ET in the 7MM was 232,688 in 2017.
The estimates show highest prevalence of ET in the United States with 142,635 cases.
Among the European five countries, France had the highest prevalent population of ET with 20,141 cases, followed by Germany and the United Kingdom. On the other hand, Spain had the lowest prevalent population of 8,360 in 2017. Japan had 19,946 prevalent cases for ET in 2017.
According to the estimates, the highest market size of ET is found in the United States followed by Japan, and Germany.
Key Benefits of Essential Thrombocythemia Market Report
-
Essential Thrombocythemia market report provides an in-depth analysis of Essential Thrombocythemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Essential Thrombocythemia market report will help in developing business strategies by understanding the Essential Thrombocythemia Market trends & developments, key players and future market competition that will shape and drive the Essential Thrombocythemia market in the upcoming years.
-
The Essential Thrombocythemia market report covers Essential Thrombocythemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Essential Thrombocythemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Essential Thrombocythemia Market
The Essential Thrombocythemia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Essential Thrombocythemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Essential Thrombocythemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Essential Thrombocythemia Epidemiology
The Essential Thrombocythemia epidemiology section covers insights about historical and current Essential Thrombocythemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Essential Thrombocythemia Drugs Uptake and Key Market Players
The Essential Thrombocythemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Essential Thrombocythemia market or expected to get launched in the market during the study period. The analysis covers Essential Thrombocythemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The objective of the treatment of ET is to prevent vascular complications such as thrombotic and hemorrhagic events because they are the leading causes of morbidity and mortality. The treatment strategy mostly depends on whether the patient is at low or high risk for thrombosis as risk stratification is used to determine the need for the patient to undergo the procedure. Generally, the low-risk patients are young with no prior thrombosis, whereas high-risk patients are older (over age 60) with a previous history of thrombosis.
The key pharma players in the Essential Thrombocythemia Market includes:
PharmaEssentia
Novartis
Imago BioSciences
Eli Lilly and Company
Geron Corporation
Italfarmaco
Shire
AOP Orphan Pharmaceuticals
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Essential Thrombocythemia Competitive Intelligence Analysis
4. Essential Thrombocythemia Market Overview at a Glance
5. Essential Thrombocythemia Disease Background and Overview
6. Essential Thrombocythemia Patient Journey
7. Essential Thrombocythemia Epidemiology and Patient Population
8. Essential Thrombocythemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Essential Thrombocythemia Unmet Needs
10. Key Endpoints of Essential Thrombocythemia Treatment
11. Essential Thrombocythemia Marketed Products
12. Essential Thrombocythemia Emerging Therapies
13. Essential Thrombocythemia Seven Major Market Analysis
14. Attribute Analysis
15. Essential Thrombocythemia Market Outlook (7 major markets)
16. Essential Thrombocythemia Access and Reimbursement Overview
17. KOL Views on the Essential Thrombocythemia Market.
18. Essential Thrombocythemia Market Drivers
19. Essential Thrombocythemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Essential Thrombocythemia Epidemiology Forecast to 2030
DelveInsight’s ‘ Essential Thrombocythemia Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Essential Thrombocythemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Essential Thrombocythemia Pipeline Insights, 2020
Essential Thrombocythemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Essential Thrombocythemia market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/